Skip to main content Skip to navigation
Hamburger Menu
Search icon
Order lookup icon Order lookup icon
Order Lookup
Country Selector Country Selector
United States (English)
Profile Icon Profile Icon
Sign-in/Register UserName
Products

Solutions

Discover & Learn

Resources & Tools

Support

Search icon Search icon
Close Menu
      Alert Icon
      BV786 Mouse Anti-Human IL-13RA2 (CD213a2)

      BD OptiBuild™ BV786 Mouse Anti-Human IL-13RA2 (CD213a2)

      Clone 47 (also known as Clone 47; mAb47; 47 mAb)

      (RUO)
      View all Formats
      Product Details
      Down Arrow Up Arrow


      BD OptiBuild™
      CD213A2; IL-13 receptor subunit alpha-2; IL-13R; IL-13Rα2; cancer/testis antigen 19
      Human (Tested in Development)
      Mouse BALB/c IgG1, κ
      Human rhIL13Ra2hFc
      Flow cytometry (Qualified)
      0.2 mg/ml
      3598
      Aqueous buffered solution containing ≤0.09% sodium azide.
      RUO


      Preparation And Storage

      Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
      Show More blue down arrow Show Less blue up arrow

      Recommended Assay Procedures

      BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation).  When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells.   However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls.  It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.

      For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime BD Horizon Brilliant dyes are used in a multicolor flow cytometry panel.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. When BD Horizon Brilliant Stain Buffer is used in in the multicolor panel, it should also be used in the corresponding compensation controls for all dyes to achieve the most accurate compensation. For the most accurate compensation, compensation controls created with either cells or beads should be exposed to BD Horizon Brilliant Stain Buffer for the same length of time as the corresponding multicolor panel. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).

      Show More blue down arrow Show Less blue up arrow

      Product Notices

      1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
      2. Researchers should determine the optimal concentration of this reagent for their individual applications.
      3. An isotype control should be used at the same concentration as the antibody of interest.
      4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
      5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
      6. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
      7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
      8. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
      9. BD Horizon Brilliant Violet 786 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,455,613; 8,575,303; 8,354,239.
      10. Cy is a trademark of Global Life Sciences Solutions Germany GmbH or an affiliate doing business as Cytiva.
      11. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
      Show More blue down arrow Show Less blue up arrow
      756125 Rev. 1
      Antibody Details
      Down Arrow Up Arrow
      47

      Clone 47 is a monoclonal antibody that specifically recognizes the Human Interleukin-13 Receptor Subunit Alpha-2 (IL-13RA2), also known as IL-13Rα2 or CD213a2. IL-13RA2 (CD213a2) is a ~42 kDa type I transmembrane glycoprotein that is encoded by IL13RA2 which belongs to the type I cytokine receptor family. The extracellular domain is comprised of three extracellular fibronectin type III domains and a WSXWS motif that is followed by a transmembrane segment and a short cytoplasmic tail. Although this receptor primarily exists in a membrane-bound form, a soluble form may be generated upon enzymatic cleavage. IL-13RA2 (CD213a2) binds IL-13 with higher affinity than the moderate affinity IL-13RA1 (CD213a) subunit of the Type II IL-4R complex. This heterodimeric receptor complex is comprised of IL-4RA (CD124) and IL-13RA1 (CD213a) and transduces signals in response to either bound IL-4 or IL-13 ligands. IL-13RA2 (CD213a2) thus appears to act as a decoy receptor due to its short cytoplasmatic tail and lack of signaling motifs and thus controls the bioavailability and activity of IL-13. It is expressed by a subset of peripheral blood lymphocytes and immature dendritic cells. It is also known as cancer/testis antigen 19 (CT19) and may be highly expressed by a variety of malignant cells including high-grade gliomas.

      756125 Rev. 1
      Format Details
      Down Arrow Up Arrow
      BV786
      The BD Horizon Brilliant Violet™ 786 (BV786) Dye is part of the BD Horizon Brilliant Violet™ family of dyes. This tandem fluorochrome is comprised of a BV421 donor with an Ex Max of 407-nm and an acceptor dye with an Em Max at 786-nm.  BV786, driven by BD innovation, is designed to be excited by the violet laser and detected using a filter, centered near 785 nm (e.g. 780/60 nm bandpass filter).  Please ensure that your instrument’s configurations (lasers and filters) are appropriate for this dye.
      altImg
      BV786
      Violet 405 nm
      407 nm
      786 nm
      756125 Rev.1
      Citations & References
      Down Arrow Up Arrow
      View product citations for antibody "756125" on CiteAb

      Development References (8)

      1. Balyasnikova IV, Wainwright DA, Solomaha E, et al. Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor α2.. J Biol Chem. 2012; 287(36):30215-27. (Biology). View Reference
      2. Hershey GK. IL-13 receptors and signaling pathways: an evolving web.. J Allergy Clin Immunol. 2003; 111(4):677-90; quiz 691. (Biology). View Reference
      3. Lupardus PJ, Birnbaum ME, Garcia KC. Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Ralpha2.. Structure. 2010; 18(3):332-42. (Biology). View Reference
      4. Penke LR, Ouchi H, Speth JM, et al. Transcriptional regulation of the IL-13Rα2 gene in human lung fibroblasts.. Sci Rep. 2020; 10(1):1083. (Biology). View Reference
      5. Tabata Y, Khurana Hershey GK. IL-13 receptor isoforms: breaking through the complexity.. Curr Allergy Asthma Rep. 2007; 7(5):338-45. (Biology). View Reference
      6. Takenouchi M, Hirai S, Sakuragi N, Yagita H, Hamada H, Kato K. Epigenetic modulation enhances the therapeutic effect of anti-IL-13R(alpha)2 antibody in human mesothelioma xenografts.. Clin Cancer Res. 2011; 17(9):2819-29. (Biology: Gel shift). View Reference
      7. Thaci B, Brown CE, Binello E, Werbaneth K, Sampath P, Sengupta S. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.. Neuro Oncol. 2014; 16(10):1304-12. (Biology). View Reference
      8. Zola H, Swart B, Nicholson I, Voss E. CD213α1 and 2. In: Zola H. Leukocyte and stromal cell molecules : the CD markers. Hoboken, N.J.: Wiley-Liss; 2007:359-360.
      View All (8) View Less
      756125 Rev. 1

       

      Please refer to Support Documents for Quality Certificates


      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For Research Use Only. Not for use in diagnostic or therapeutic procedures.